The global cartilage repair market size is calculated at US$ 1.51 billion in 2024, grew to US$ 1.77 billion in 2025, and is projected to reach around US$ 7.32 billion by 2034. The market is expanding at a CAGR of 17.14% between 2025 and 2034.
Rising Investment by Market Players: Cartilage damage is growing, especially in women. This has developed the interest of key players, and they are investing in the market, leading to the growth of the market.
The identification and amplification of stem/progenitor cells, the development of growth factor cocktails to promote differentiation, the production of efficient biomaterial scaffolds for cell delivery, the management of inflammation, and the development of strategies to improve cell integration and retention within the injured tissue are important research areas.
Determining clinical needs, performing preclinical research and regulatory interactions (such as pre-IND meetings), conducting phased human clinical trials with precisely defined patient populations, endpoints, and comparator groups, and then submitting all data for regulatory review and market approval by organisations such as the FDA are the steps involved in cartilage repair clinical trials and regulatory approval.
Accurate diagnosis through imaging and physical examinations is the first step in providing patient support and services for cartilage repair. Next comes a customised treatment plan that may include conservative measures like medication and physical therapy or more invasive procedures like cell-based therapies and cartilage/bone grafts.
In January 2024, as previously revealed, Smith+Nephew paid $180 million upon completion, with an additional $150 million depending on future financial success. Agili-C has the potential to revolutionise cartilage repair results due to its demonstrated superiority over the existing standard of care, according to Scott Schaffner, President, Sports Medicine, Smith+Nephew. I am really certain that this will significantly add value for Smith+Nephew because of our leadership in knee repair and our proficiency in regenerative treatment.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
